

ANNUAL REPORT **2018**

Health Research Institute of
Santiago de Compostela

EDITION AND PRODUCTION

Technical Secretary of the Health Research Institute of Santiago de Compostela

Isabel Lista García. Quality Manager.

Yolanda Liste Martínez. Technical Management.

José Ramón Castro Ruibal. Technical Research Management and Promotion.

APROBATION

Direction Board of the institute met in **Santiago de Compostela** on **15 March 2019**

ANNUAL REPORT **2018**

Health Research Institute of
Santiago de Compostela



José Castillo Sánchez

Director científico
Scientific Director

"A visibilidade e difusión das actividades é un elemento de importancia para dar a coñecer a nosa actividade investigadora como recoñecemento do noso esforzo"

"The visibility and dissemination of the activities is an important element to publicize our research activity as recognition of our effort"

Unha vez máis, é un pracer presentar a memoria do IDIS, esta ofrécenos unha panorámica das melloras implantadas, os avances obtidos e dos resultados acadados durante o 2018, pero tamén é un reflexo dos obxectivos aínda non alcanzados. É difícil sintetizar nun documento o traballo colectivo dos investigadores, técnicos e xestores que formamos o instituto, pero de algunha maneira, este informe pretende reflexar reflectir o rendemento de todos e o impulso que a investigación biomédica ten no ámbito asistencial e académico da área de Santiago de Compostela e Lugo.

A visibilidade e difusión das actividades é un elemento de importancia para dar a coñecer a nosa actividade investigadora como recoñecemento do noso esforzo. Pero o obxecto desta memoria, non só é útil para presentar os nosos logros, senón que é moi valioso para observar que cousas se teñen feito, en que medida acadamos os obxectivos, como o estamos facendo en comparación cos anos anteriores e que podemos mellorar, é dicir, ofrécenos a posibilidade de realizar unha análise estratéxica do desenvolvemento do instituto.

A nosa razón de ser consiste na aplicación dos resultados da investigación básica e clínica no sistema sanitario, e esta idea estase a afianzar nos nosos grupos que, cun marcado carácter multidisciplinar, enfocan

Once again, it is my pleasure to present the IDIS annual report. This is an overview of the implemented improvements, the progress made and the results achieved during the past 2018, but it is also a reflect of the unmeet goals. It is difficult to summarize in one single document the collective work of all researchers, technicians and managers that form the institute, but in some way, this report aims to reflect everyone´s performance and the impetus that biomedical research has in the clinical and academic area of Santiago de Compostela and Lugo.

The visibility and dissemination of the activities is an important element to publicize our research activity as recognition of our effort. However, the purpose of this report is not only to present our achievements, but also to observe what have been done, to what extent we achieve the objectives, how we are doing in comparison with previous years and what we can improve. In summary, it offers the possibility of carrying out a strategic analysis for the institute´s development.

Our raison d'être relies in the application of the results of basic and clinical research to the health system, and this idea is taking hold in our groups that, with a marked multidisciplinary nature, focus their work to respond to the demands arising from the clinic. Our contributions to science position



os seus traballos para dar resposta ás demandas xurdidas da área clínica. As nosas aportacións á ciencia nos sitúan na cabeza da investigación biomédica en Galicia e nunha destacada posición no ámbito nacional, ademais, o crecemento constante da participación dos membros dos nosos equipos en proxectos de investigación europeos danos unha forte proxección internacional.

A análise das actividades e os indicadores amósanos unha evolución positiva, seguindo a tendencia das anualidades anteriores. Todo isto foi posible grazas ao esforzo de todas as persoas que integramos o IDIS, así como do apoio institucional das entidades que o conforman. Podemos considerar que una das nosas grandes fortalezas é o excelente potencial humano, o seu coñecemento e implicación garanten a continuidade da nosa produción.

Ademais da produción científica, a transferencia de resultados e da captación de recursos, no noso informe podemos observar o compromiso da nosa institución coa formación en investigación biomédica. A implicación na dirección de teses de doutoramento e o apoio á incorporación de persoal na etapa de formación garanten a base do IDIS do futuro.

Podemos concluír que entre todos estase a facer un gran traballo, xerándose grandes expectativas de crecemento, e isto representa a mellor garantía de continuidade. Evitemos a miopía que pode suprimir a fragmentación; sen comportas o futuro está asegurado.

Moitas grazas.



us at the head of biomedical research in Galicia and in an outstanding situation in Spain. In addition, the constant growth of the number of members of our teams participating in European research projects gives us a strong international projection.

The activity analysis and the research indicators show a positive evolution, following the trend of previous years. Everything has been possible thanks to the efforts of all the people who make up the IDIS, as well as the institutional support. We can consider that one of our great strengths is the excellent human resources. Their knowledge and implication guarantee the continuity of our production.

In addition to the scientific production, the results transfer and the fundraising, in our report we can observe the commitment of our institution with the training in biomedical research. The involvement in the direction of doctoral theses and the support for the incorporation of personnel in training stages guarantee the base of the future IDIS.

We can conclude that among all we are doing a great job, generating great expectations for growing, and this represents the best guarantee of continuity. Let's avoid myopia that can suppress fragmentation; without gates the future is assured.

Thank you.

SUMMARY

1 EXECUTIVE SUMMARY

The **Biomedical Research Institute of Santiago de Compostela** is a translational research centre for innovation and transfer knowledge that optimizes existing synergies between the *Xerencia de Xestión Integrada de Santiago de Compostela* and the *University of Santiago de Compostela*. It is accredited as a medical research centre of the *National Health System by the Institute of Health Carlos III*.

MISSION

We are a translational biomedical research centre that joins professionals with a shared objective: to improve people's health

VISION

We want to become a reference as an organizational and governance model, encouraging participation, collaboration and transparency

VALUES

Responsibility
Continuous improvement
Horizontal communication
Transformative research
Integration
Leadership

TOTAL FUNDS RAISED

29.108.535,46 €

65
Projects

289
Donations

104
Clinical trials

58
Staff contracts

415
Contracts and provision of services

178
Observational studies

754
Published articles

24
Training exchanges

7
Granted patents

57
Thesis

220
Professional training placement

30
Requested patents

79
Seminars

2 GLOBAL ANALYSIS

Number of **groups per area**

- Oncology
- Genetics and Systems Biology
- Endocrinology
- Neurosciences
- Platforms and Methodology
- Inflammation

There is also a support área *(technical secretariat and common support platforms for research)* with 3 groups.



History of a joint venture: **human resources in figures**

1.071 people






25%
24%
28%
23%
Senior Researchers
Posdoctoral Researchers
Predoctoral Researchers
Support Staff
936
1064
1071
38%
62%
35%
65%
31%
69%
2016
2017
2018
60%
40%
33%
67%
30%
70%
Fundamental Researchers
Medical Staff

Number of **researchers per area**




82
groups
39
groups
621
researchers
Consolidated
33
groups
298
researchers
Emerging
10
groups
124
researchers
Clinical partners

Number of **published articles each year**

The Institute has published **754 original scientific articles, editorials and reviews** in 466 international journals indexed in the *Journal Citation Report* with an **cumulative impact factor** of **3.569 points.**



Cumulative **impact factor**

The upward trend of the cumulative impact factor is maintained and it moves from 1.308 in 2010 to **3.569 in 2018**.



Average **impact factor**



Number of **published articles in the first decile**

A remarkable increase in the first decile for the same period from 68 articles published in 2010 to **160 in 2018**.



Number of **articles** **by year published in each quartile**



Number and % of **the total number of publications and articles in 2018**

The number of articles per quartile **increased gradually during the period of 2010-2018 almost in every quartile and every year**.

Taking into account the relevance of the authors in the articles signature, we identify those in which the first or the last author is assigned to an IDIS group. We define them as articles of our own.





312

Articles published in collaboration between the groups of the centres outside of spain

154

Articles published in collaboration between the IDIS groups

Number and % of **articles published in collaboration between the IDIS groups and the groups of the centres outside of Spain.**

In 2018, 20,42% of the work were carried out by teams in which members of more than one IDIS group were involved.

43,38% were done in collaboration with researchers from centres outside of Spain.



During 2018, the funds raised in competitive calls for **research projects**, the **recruitment of staff**, **infrastructures**, **agreements**, **contracts and provision of services**, **donations**, **clinical trials and observational studies** generated **29.108.535,46 €** which will complement the resources of the institutions that take part in IDIS.

AMOUNT

29.108.535,46 €

Summary of **the funds raised in 2018**

CONCEPT	NUMBER	AMOUNT
Projects	65	**10.631.222,46 €**
Human resources	58	**4.781.190,00 €**
Donations	289	**1.040.133,81 €**
Contracts and provision of services	415	**6.622.804,20 €**
Transfer	2	**46.445,65 €**
Infrastructure	2	**1.364.206,77 €**
Studies *(Clinical Trials, Observational Studies)*	282	**4.622.532,23 €**

2018

AMOUNT RAISED

29.108.535,46 €


18.705.130 €
21.731.549 €
23.638.401 €
32.402.824 €
29.108.535 €
2014
2015
2016
2017
2018

Number and amount of **funds raised in 2018 for projects by location**

65 Projects
10.631.222,46 €





Amount of **funds raised by year for projects**



Number of **clinical trials and observational studies**



104
CLINICAL TRIALS

60 National
24 International
20 Local

178
OBSERVATIONAL STUDIES

96 National
35 International
41 Local
6 Regional

3 STRUCTURE


DIRECTION BOARD
External Scientific Committee
Research Committee
Quality Committee
Primary Care Committee
Education Committee
SCIENTIFIC DIRECTION
Technical Secretary
Fundación Instituto de Investigación Sanitaria (FIDIS)
USC Management and Enhancement of I+D+i Area
AREAS
GROUPS
COMMON PLATFORMS

Government bodies

PRESIDENT
Jesús Vázquez Almuíña

VICE-PRESIDENT
Antonio López Díaz

CHAIRS
Julián Álvarez Escudero
José Ramón González Juanatey
Luis Lima Rodríguez
Beatriz Allegue Requeijo
Eloína Núñez Masid
Isabel Rodríguez-Moldes Rey
María Gómez-Reino Garrido (without vote)
José Castillo Sánchez (without vote)

SCIENTIFIC DIRECTION
José Castillo Sánchez

Advisory bodies

EXTERNAL SCIENTIFIC COMMITTEE

Ángeles Almeida Parra
Melchor Álvarez de Mon Soto
María del Carmen Ayuso García
Joan Xavier Comella Carnicé
Xosé García Bustelo

RESEARCH COMMITTEE

PRESIDENT
Federico Martinón Torres

SECRETARY
Isabel Lista García

Francisco Campos Pérez
Carlos Diéguez González
Miguel García González
María Gómez-Reino Garrido
Javier González Barcala
Julio Iglesias García
María Jesús Lamas Díaz
Carlos Peña Gil
Alberto Ruano Raviña
Antonio Salas Ellacuriaga

Advisory bodies

PRESIDENT
Estrella López Pardo

SECRETARY
Isabel Lista García

Gerardo Atienza Merino
Ángeles Fernández Rodríguez
Uxía Ferrer Ozores
Carmen Ruth González Diéguez
Carlos Grande Sellera
Mar Lale Candal
Pablo Mosquera Martínez

PRESIDENT
Tomás Sobrino Moreira

SECRETARY
Isabel Lista García

Clara Álvarez Villamarín
Miguel Ángel Caínzos Fernández
Manuel Collado Rodríguez
Fernando Domínguez Puente
José Antonio Ferreiro Guri
Miguel Gelabert González
Arturo González Quintela
Francisco Gude Sampedro
Celia María Pombo Ramos
Anxo Vidal Figueroa

Advisory bodies

PRIMARY CARE COMMITTEE

PRESIDENT
Manuel Portela Romero

SECRETARY
Yolanda Liste Martínez

Paula Antelo País
Rosendo Bugarín González
Rosa Ana Castelo Domínguez
Sergio Cinza Sanjurjo
Carmen Fernández Merino
Pilar Gayoso Diz
Daniel Rey Aldana
Jesús Sueiro Justel
Xoán Vázquez Lago
Manuel Vidal Fernández Fernández

TECHNICAL SECRETARY

Isabel Lista García
Yolanda Liste Martínez
José Ramón Castro Ruibal

A001 ONCOLOGY *Coordinator:* ***Rafael López López***

C010	**Genetics of Human Diseases**	*Fernando Domínguez Puente*
C011	**Pathology**	*José Ramón Antúnez López*
C025	**NANOBIOFAR**	*María José Alonso Fernández*
C030	**Traslational Medical Oncology**	*Rafael López López*
C032	**Molecular Imaging**	*Álvaro Ruibal Morell*
E004	**Molecular Oncology**	*José Antonio Costoya Puente*
E018	**Cell Cycle and Oncology (CiClon)**	*Anxo Vidal Figueroa*
E028	**Stem Cells in Cancer and Aging**	*Manuel Collado Rodríguez*
E031	**Oncologic Endocrinology**	*Román Pérez Fernández*
E032	**Preclinical Animal Models**	*Laura Sánchez Piñón*
E033	**Viruses and cancer**	*María del Carmen Rivas Vázquez*
E037	**DNA Repair and Genome Integrity**	*Miguel González Blanco*
AC01	**Lymphoproliferative Disorders**	*José Luis Bello López*
AC06	**Intraocular Tumours in Adults**	*Antonio Piñeiro Ces*
AC08	**Surgical Oncology**	*Manuel Bustamante Montalvo*

A002 GENETICS AND SYSTEMS BIOLOGY

Coordinator: ***Ángel Carracedo Álvarez***

C005	**Genetics**	*Ángel Carracedo Álvarez*
C009	**Translational Research in Digestive Diseases**	*Juan Enrique Domínguez Muñoz*
C020	**Genetics, Vaccines, Infections and Paediatrics (GENVIP)**	*Federico Martinón Torres*
E012	**Comparative Genomics of Human Parasites**	*Julio Manuel Maside Rodríguez*
E015	**Population Genetics in Biomedicine (GenPoB)**	*Antonio Salas Ellacuriaga*
E016	**Genetics of Neurological Disorders**	*María Jesús Sobrido Gómez*
E017	**Cancer Genetics and Rare Diseases**	*Ana Paula Vega Gliemmo*
E020	**Psychiatric Genetics**	*Javier Costas Costas*
E021	**Genetics and Developmental Biology of Kidney Diseases**	*Miguel Ángel García González*
E027	**Escherichia coli**	*Jorge Blanco Álvarez*
E035	**Genetics of Gastrointestinal Tumours**	*Clara Ruiz Ponte*
E036	**Stem Cells and Human Diseases**	*Miguel Ángel Fidalgo Pérez*
E040	**Mobile Genomes and Disease**	*José Manuel Castro Tubío*

A003 ENDOCRINOLOGY

Coordinator: ***Felipe Casanueva Freijo***

C001	**Neoplasia and Endocrine Differentiation**	*Clara Álvarez Villamarín*
C006	**Molecular Endocrinology**	*Felipe Casanueva Freijo*
C008	**Obesity and Nutrition**	*Carlos Diéguez González*
C012	**Metabolic Disorders**	*María de la Luz Couce Pico*
C019	**Thyroid and Metabolic Disorders Unit (UETeM)**	*David Araújo Vilar*
C022	**Paediatric Nutrition**	*Rosaura Leis Trabazo*
C029	**Neurobesity**	*Miguel López Pérez*
C031	**Molecular Metabolism**	*Rubén Nogueiras Pozo*
E006	**Cytokines and Obesity (Citobes)**	*María del Carmen García García*
E023	**Obesidomics**	*María Pardo Pérez*
E025	**Cellular Endocrinology**	*Jesús Pérez Camiña*
E026	**Endocrine Physiopathology**	*Luisa María Seoane Camino*
E039	**Diabesity**	*Sulay Tovar Carro*
E041	**Epigenomics in Endocrinology and Nutrition**	*Ana Belén Crujeiras Martínez*
AC04	**Paediatric Endocrinology**	*Manuel Pombo Arias*

A004 NEUROSCIENCES

Coordinator: ***José Castillo Sánchez***

C004	**Neurobiology**	*Antonio Canedo Lamas*
C007	**Clinical Neurosciences (LINC)**	*José Castillo Sánchez*
C015	**Neurobiology of the Visual System**	*Francisco González García*
C018	**Experimental Neurology of Parkinson´s Disease**	*José Luis Labandeira García*
C026	**BIOFARMA**	*María Isabel Loza García*
C033	**Design, Synthesis and Medical Evaluation of Bioactive Compounds and New Materials**	*Antonio Mouriño Mosquera*
C034	**Physics of Polymers and Colloids**	*Victor Mosquera Tallón*
C035	**R&D in Drugs Dose Forms and Delivery Systems**	*Ángel Concheiro Nine*
C036	**Magnetism and Nanotechnology (NanoMag)**	*José Rivas Rey*
C037	**Trace Elements, Spectroscopy and Speciation**	*Pilar Bermejo Barrera*
C038	**Analytical Chemistry of Compounds of Alimentary, Environmental and Biological Interest**	*Antonia María Carro Díaz*
E014	**Prion Diseases**	*Jesús Rodríguez Requena*
E019	**Cell Stress**	*Juan Bautista Zalvide Torrente*
E029	**Cognitive Neuroscience**	*Fernando Díaz Fernández*
AC03	**Critical Patient**	*Julián Álvarez Escudero*
AC11	**Life Support and Medical Simulation**	*Antonio Rodríguez Núñez*

A005 PLATFORMS AND METHODOLOGY

Coordinator: ***Juan Jesús Gestal Otero***

C002	**Experimental Surgery**	*Miguel Ángel Caínzos Fernández*
C013	**Epidemiology, Public Health and Evaluation of Health Services**	*Adolfo Figueiras Guzmán*
C017	**Research Methodology**	*Francisco Gude Sampedro*
C021	**Clinical Analysis**	*Santiago Rodríguez-Segade Villamarín*
C024	**Radiology**	*Miguel Souto Bayarri*
E002	**Biostatistics**	*Carmen María Cadarso Suárez*
E013	**Microbiology**	*María Luisa Pérez del Molino Bernal*
E034	**Clinical Pharmacology**	*María Jesús Lamas Díaz*
AC09	**Oral Sciences (OSRG)**	*Inmaculada Tomás Carmona*
AC10	**Healthy ageing, fragility and chronicity. Research in Primary Care**	*Juan Manuel Vázquez Lago*

A006 INFLAMMATION

Coordinator: ***José Ramón González Juanatey***

C003	**Hypertension**	*Carlos Calvo Gómez*
C014	**Rheumatology**	*Juan Jesús Gómez-Reino Carnota*
C016	**Cardiology**	*José Ramón González Juanatey*
C027	**Neuroendocrine Interactions in Rheumatic and Inflammatory Diseases (Neirid)**	*Oreste Gualillo*
C028	**Experimental and Observational Rheumatology**	*Antonio González Martínez-Pedrayo*
C039	**Biodiscovery HULA-USC**	*Luis Miguel Botana López*
C040	**Oral Medicine and Surgery (OMEQUI)**	*Pedro Diz Dios*
E001	**Cardiovascular Genetics**	*María José Brión Martínez*
E009	**Cellular and Molecular Cardiology**	*Francisca Lago Paz*
E030	**Platelet Proteomics**	*Ángel García Alonso*
E038	**Musculoskeletal Pathology**	*Rodolfo Gómez Bahamonde*
AC05	**Pneumology**	*Luis Guillermo Valdés Cuadrado*
AC07	**Semergal**	*Sergio Cinza Sanjurjo*


ANNUAL REPORT **2018**

4 RECURRENT TRAINING

Training activities in 2018

In 2018, 79 seminars were organized, 57 doctoral thesis were directed by IDIS' researchers, 220 professional training placement and 24 short training exchanges were organized in collaboration with the *Medicina Intercambios Galicia Association (ME.I.GA.)*, member of the *International Federation of Medical Students' Associations (IMFSA)*.

79
Seminars

57
Doctoral thesis

220
Professional training placement

24
Short training exchanges

Number of **thesis each year**




ANNUAL REPORT **2018**

5 INNOVATION AND TRANSFER

- Transfer acceleration through public funding and private investment.
- Adopting the Public-Private Partnership Model.
- Partnering.
- Disseminating our research.
- Intelectual property.



Transfer acceleration through public funding and private investment

ITEMAS network

Innovation in Medical and Heath Technologies Network funded by the Instituto de Salud Carlos III.

CÓDIGO MÁIS project

Valorization program of SERGAS and USC.

GNICIA

The IGNICIA Proof of Concept programme of the Galician Innovation Agency (GAIN) aims to enhance and support the transfer of research results generated by knowledge centres. IGNICIA seeks to accelerate and increase technology transfer, detecting projects with innovative and market potential, contributing to the profitability of public investment in research.

IDIS requested 16 projects and one of them was granted.

Atlantic Ket Med

Atlantic KET Med (AKM) is an Interreg funded, coordinated action aiming to establish a Transnational Advanced Pilot Manufacturing Ecosystem for Future Biomedical Products. Featuring partners with expertise in the Key Enabling Technologies (KETs), AKM plans to provide bottom-up support to the ecosystem through direct support of SMEs as well as top-down support through educational and infrastructure policies.

IDIS joins the ecosystem and it´s the only Spanish research centre that participates in AKM.



Adopting the Public-Private Partnership Model

Two P2 ongoing initiatives where public IDIS partners share risks with private investors.

Roche-CHUS, Precision Oncology Joint Unit.

Esteve-USC, Drug Discovery Joint Unit.

Partnering

TITTAN

A European Network for Technology, Innovation and Translation in Ageing, it aims to tackle that challenge, by improving the quality and performance of the European regional healthcare systems in relation with the healthy and active ageing. IDIS participates acts as a stakeholder.



BioInvestor Day

BIOSPAIN is the first biotech country based event in Europeorganized by a national bioindustry association and one of the largest in the world by number of one-to-one meetings and number of participants companies.

Following the success of previous editions, BIOSPAIN 2018 (celebrated in Sevilla, Spain) hosted 773 attendees, more than 773companies and institutions and over 1,550 delegates from 31 countries. Participating major companies, institutions, research centers of the Spanish biotechnology sector.

IDIS participated in Biospian and made contact and interviewed more than 30 potential partners.

BioINCUBATECH

BioIncubaTech is the High Technology Incubator for the promotion of innovation and biotechnology transfer in the field of health and food technologies to micro-SMEs. BioIncubaTech belongs to “High Technology Incubators for the promotion of innovation and technology transfer to micro-SMEs” Project, aimed to modernize the regional productive fabric. These Incubators are created as traction instruments aligned with the objectives of the EU 2020 and Horizon 2020 Strategy and will promote inter-regional cooperation, as well as collaboration between public and private sector agents at international level.

IDIS collaborates since the beginning of this proposal and helped to create the project.

Intelectual property

30 Request

8 European Application
7 National Phases
8 PCT Application
6 Spanish Application
1 USA Application



7 Granted

6 Spain (licensed)
1 United States of America

2 Software






ANNUAL REPORT **2018**

6 PLATFORMS


USC
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
CAMPUS VIDA
CAMPUS DE EXCELENCIA INTERNACIONAL
CiMUS
SERVIZO GALEGO de SAÚDE
Citometry
Epidemiology And Clinical Research Unit
The Animal Experimentation Unit
Microscopy
Sequencing And Fragment Analysis Unit
9,4 Magnetic Resonance
Molecular Imaging Unit Micropet/spect/ct Scan


Liquid Biopsy Unit
Proteomics
Pet Radiopharmacy Unit Galicia Cyclotron
Imaging
:Bibliosaúde
Biobank
Drug Screening Platform (Usef)
Radiophysics Laboratory
Genomics
Experimental Biomedicine Centre (Cebega)
bugalicia

Proteomics

Susana Belén Bravo López
susana.belen.bravo.lopez@sergas.es

The proteomics platform was created to enhance, give support and offer a complete infrastructure in the field of proteomics to the Institute's researchers and other public and private bodies. It is equipped with the latest generation technology that allows the development of both studies of characterisation of complete proteomes as well as studies of analysis of differential expression.

Liquid Biopsy Unit

Laura Muinelo Romay
laura.muinelo.romay@sergas.es

The service for the analysis of circulating cells works with the CellSearchTM system (Veridex) that allows, through the use of immunomagnetic techniques of enrichment and identification by immunofluorescence, isolate and quantify present cells in peripheral blood. Its main application is aimed to the detailed analysis of circulating tumor cells (CTC), even though the computer also allows identify other kind of cells such as endothelial. In addition, the platform has the capacity to carry out studies with circulating DNA.

Flow Citometry

Tomás Sobrino Moreiras
tomas.sobrino.moreiras@sergas.es

It is a technique of cells analysis that allows one to measure the characteristics of light scattering and fluorescence that cells have when they pass through a ray of light. This platform's main aims are:

- To advise users of the IDIS on the principles and applications of flow cytometry analysis and cell sorting.
- To develop, optimize and perform new analytic applications demanded by the users of the IDIS.
- To do cellular isolation through cell sorting.
- Quantify different soluble cytokines using multiplex tests.

Magnetic Resonance Imaging

Ramón Iglesias Rey
ramon.iglesias.rey@sergas.es

Magnetic Resonance Imaging is perhaps the most versatile neuroimaging technique that exists today. The use of this platform in its different variants (anatomical, functional, spectroscopy and molecular imaging) allows one to perform a complete follow-up, non-invasive (in vivo) and longitudinal in time of the process associated with neurovascular diseases and other such as plasticity, reorganization and functional recovery in animal models.

Biobank

Lydia Fraga Fontoira
(Manager)
Phone. (+34) 981 955 148
biobanco.apa.santiago@sergas.es
lydia.fraga.fontoira@sergas.es

It is a store of biological samples associated with clinical information, which are collected, processed and handled with quality and excellence criteria. The objective is to implement them, in a non-profit way, to serve the medical community in order to promote biomedical research. Biobanks can be directly aimed at diseases (e.g., Bank of Tumours) or at population and epidemiological outbreaks.

Biobanks are essential tools to make biomedical research easier. That is why they are so relevant and also for the increasing demand of the highest quality biological samples in order to develop research processes.

Molecular Imaging Unit

Pablo Aguiar Fernández
pablo.aguiar.fernandez@sergas.es

Our mission is to bridge the gap between in vitro biomedical research and in vivo preclinical and clinical imaging, providing novel molecular imaging biomarkers and imaging probes to gain information about physiology and pathology in vivo. We offer a core facility to provide opportunities for in vivo molecular imaging based on PET, SPECT and CT technologies.

The Animal Experimentation Unit

Francisco Campos Pérez
francisco.campos.perez@sergas.es

The Animal Experimentation Unit provides support in biomedical research with several animal models for IDIS research groups, in strictly controlled sanitary and environmental conditions. The Animal Experimentation Unit is accredited by the Ministry of Rural Environment of the Xunta de Galicia. It has rat and mouse housing facilities, surgery rooms and specialized qualified personnel, in accordance with current regulations. It also has an Ethics Committee on Animal Experimentation. It obtained the corresponding accreditation as an Authorized Body to carry out the evaluation of projects from a scientific or educational point of view.

It is responsible for advice on issues related to animal welfare, review of internal operational processes, issuance of reports and monitoring of projects. Its objective is to promote research, and to develop and implement biomedical training, providing professionals with the necessary resources for the development of these initiatives.

Confocal Microscopy

Marta Picado Barreiro
marta.picado.barreiro@sergas.es

The confocal scanning microscope is well-known for its ability to perform optical sectioning: a thin plane or section within a thick turbid medium is non-invasively imaged with high resolution and contrast. Real-time in vivo confocal fluorescence microscopy. Nuclear, cellular and morphologic detail is imaged in living intact tissue without having to excise physically and prepare thin sections or cultures.

The services include the infrastructure and specialised staff to perform analysis as...

- 3D imaging reconstruction
- Multiple labeling
- Colocalization
- In vivo fluorescence imaging


ANNUAL REPORT **2018**

7 COMPETITIVE FUNDING

During 2018, **29.108.535,46 €** were raised in the following concepts: projects, human resources, transfer, donations, contracts, infrastructures, provision of services, agreements and studies.

TOTAL

29.108.535,46 €

65
Projects
10.631.222,46 €

289
Donations
1.040.133,81 €

58
Human resources
4.781.190,00 €

415
Contracts and provision of services
6.622.804,20 €

282
Studies (Clinical Trials, Observational Studies)
4.622.532,23 €

2
Transfer
46.445,65 €

2
Infrastructures
1.364.206,77 €

65 PROJECTS

10.631.222 €

2.395.694 €	7 International projects
4.413.741 €	46 National projects
3.821.785 €	12 Regional projects

58 Human resources
4.781.190,00 €

CONCEPT	NUMBER	AMOUNT
FPU Grant	5	**397.986,12 €**
Juan de la Cierva	2	**116.000,00 €**
Juan Rodés	1	**180.000.00 €**
MA-E Grant	1	**6.000,00 €**
Río Hortega	3	**161.196,00 €**
Predoctoral i-PFIS Grant	1	**82.400,00 €**
Predoctoral PFIS Grant	3	**247.200,00 €**
Postdoctoral Grant	12	**1.037.106 €**
Predoctoral Grant	26	**2.263.637,34 €**
Bioinforming Technician	1	**53.732,00 €**
MARIE CURIE_Ind.Fellowship	1	**160.932,48 €**
Technical Assistant PTA Grant	2	**75.000,00 €**

2018
58 Human resources
4.781.190 €

2017
40 Human resources
3.418.075 €

Postdoctoral Grant



Predoctoral Grant

ANNUAL REPORT **2018**

8 STRATEGIC ALLIANCES

PLATFORMS

3

RED BIOBANCOS

ITEMAS ISCIII

SCREN. Spanish Clinical Research Network ISCIII

CIBER

6 NETWORKS FOR COOPERATIVE RESEARCH IN HEALTH

CIBEROBN (1), Physiopathology of Obesity and Nutrition

CIBERER, Rare Diseases

CIBERESP, Public Health and Epidemiology

CIBERCV: Cardiovascular Diseases

CIBERONC: Cancer

CIBER CIBERNED: Neurodegenerative Diseases

(1) Scientific Direction IDIS

RETICS

8

BIOMEDICAL RESEARCH NETWORKING CENTRES

- INVICTUS (1), Cerebrovascular diseases (stroke)
- RIC, Cardiovascular Diseases
- OFTARED, Eye Diseases
- REDIAPP, Research Network on Preventive Activities and Health Promotion in Primary Care
- RIER, Rheumatic Diseases
- REDINREN, Kidney Diseases
- Cell Therapy Network
- BIOBANK

(1) Scientific Direction IDIS

OTHERS

2

EATRIS
European Infrastructure for Translational Medicine

EIBIR
EUROPEAN INSTITUTE FOR BIOMEDICAL IMAGING RESEARCH


ANNUAL REPORT **2018**


9
AREAS


A001
Oncology
196
A002
Genetics and Systems Biology
203



PEOPLE

1.071 are integrated in **82 groups**

6 RESEARCH AREAS

754
Publications

Publications
in 2018






8
7
6
5
4
3
6,34
5,17
4,25
4,28
2,95
5,07
Oncology
Genetics and Systems Biology
Endocrinology
Neurosciences
Platforms and Methodology
Inflammation


1000
800
600
400
703,8
858,3
497,3
752,9
372,2
848
Oncology
Genetics and Systems Biology
Endocrinology
Neurosciences
Platforms and Methodology
Inflammation

$$\sum fi$$





Thesis



Patents



Projects

10.631.222,46€



Contracts

6.622.804,20€



Clinical Trials

4.622.532,23€


idis

ANNUAL REPORT **2018**

XUNTA DE GALICIA
CONSELLERÍA DE SANIDADE